Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Ready to Announce with Confidence?
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in ARS Pharmaceuticals to Contact Him Directly to Discuss Their Options
New York, New York--(Newsfile Corp. - September 3, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals" or the "Company") (NASDAQ: SPRY).
[You may also click here for additional information]
WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of all investors who purchased or otherwise acquired ARS securities between March 9, 2026, and June 24, 2026, inclusive (the "Class Period").
WHAT TO DO NEXT: To learn more about the ARS Pharmaceuticals class action, go to www.faruqilaw.com/SPRY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). A class action lawsuit has already been filed.
If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
THE ALLEGATIONS:
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark.
Faruqi & Faruqi, LLP also encourages anyone with information regarding ARS Pharmaceuticals' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Frequently Asked Questions (FAQ) for Investors Regarding the ARS Pharmaceuticals Securities Class Action Lawsuit
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired ARS Pharmaceuticals (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
How much did ARS Pharmaceuticals stock drop?
Following the alleged corrective disclosures, ARS Pharmaceuticals shares fell approximately 24% on June 25, 2026, as described in the complaint.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased ARS Pharmaceuticals securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312831
Source: Faruqi & Faruqi LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies in the Banking / Financial Services industry.
Faruqi & Faruqi, LLP Urges UWM Holdings Corporation (UWMC) Investors to Seek Counsel Before the October 12, 2026 Lead Plaintiff Deadline in the Securities Class Action
2026-09-03 1:12 PM EDT
Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action
2026-09-03 1:11 PM EDT
Faruqi & Faruqi, LLP Urges Alarum Technologies (ALAR) Investors to Seek Counsel Before October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action
2026-09-03 12:54 PM EDT
Jan 30, 2026
To understand where public relations and investor communications are headed, we analyzed over 39,000 press releases distributed in 2025. The data is clear: success now depends on a careful balance between AI-readability and human trust. More than 50% of news activity on the TMX Newsfile network is now driven by AI bots from OpenAI and Microsoft. Yet these systems rely on human-verified facts to ground their answers. We have entered a “ zero-click ” reality, where Generative AI systems...
Litigation and Regulation
Banking / Financial Services